ArticlePloS one2025
Microbiota-supportive diets and hyperlipidemia: The mediating role of systemic inflammation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperlipidemia is a major modifiable risk factor for cardiovascular disease, and emerging evidence suggests a critical role of the gut microbiota in lipid metabolism. The Dietary Index for Gut Microbiota (DI-GM) is a novel tool designed to capture the microbiota-supportive potential of habitual dietary patterns, yet its association with lipid abnormalities remains underexplored in large populations.
methodsWe analyzed data from 21,352 adults in the 2010-2020 cycles of the National Health and Nutrition Examination Survey (NHANES). The DI-GM, reflecting 14 microbiota-relevant dietary components, was derived from 24-hour recall data. Hyperlipidemia was defined using standard lipid thresholds or lipid-lowering medication use. Survey-weighted logistic regression, restricted cubic spline analysis, and mediation analysis using the systemic immune-inflammation index (SII) were performed to assess associations and potential mechanisms.
resultsHigher DI-GM scores were significantly associated with lower odds of hyperlipidemia (fully adjusted OR for highest vs. lowest category = 0.806; 95% CI: 0.735-0.883). A dose-response relationship was confirmed in spline models. Mediation analysis showed that systemic inflammation, as quantified by SII, accounted for 17.8% of the observed association, suggesting an immunometabolic pathway linking diet and lipid status.
conclusionMicrobiota-oriented dietary patterns, as captured by the DI-GM, are inversely associated with hyperlipidemia in U.S. adults. These findings highlight the value of integrating microbiome-relevant dietary assessment into lipid management strategies. Partial mediation by systemic inflammation underscores a potential mechanistic link warranting further investigation through longitudinal and interventional studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.